Xtherapeutics ApS: Financial statements 2018
CVR: 37384089
Source: annual report 2018, Danish Business Authority
01/07/2017 – 30/06/2018
Xtherapeutics ApS (CVR 37384089) has filed annual accounts for 2018. In 2018, the company reported a net result of DKK -7,500. Equity in the 2018 report amounted to DKK -7,499.
- Profit/Loss
- DKK -7,500
- Equity
- DKK -7,499
- Total Assets
- DKK 1
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2018
As of August 21, 2018, Thomas Lars Andresen is registered as adm. dir. of Xtherapeutics ApS.
As of August 21, 2018, Anders Elias Hansen has stepped down as adm. dir. of Xtherapeutics ApS.
On August 21, 2018, the company changed its name from Vaccex IVS to Xtherapeutics IVS.
As of June 21, 2018, Jonas Rosager Henriksen is registered as an owner of Xtherapeutics ApS with an ownership share of 20%.
About Xtherapeutics ApS
Xtherapeutics ApS is a Danish company of the type Anpartsselskab based in Charlottenlund, founded in 2016. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Xtherapeutics IVS and Vaccex IVS. The management consists of Thomas Lars Andresen. The company is owned by Jonas Rosager Henriksen, Anders Elias Hansen and TLA-HOLDING 2010 ApS. In 2025, the company reported a gross profit of DKK 0 and a net result of DKK 0 compared with DKK -14,323 the year before. Equity in the 2025 report amounted to DKK -18,439.